BREEDING BIOLOGY OF GREATER SANDHILL CRANES ON THE ROSEAU RIVER WILDLIFE MANAGEMENT AREA, MINNESOTA

The breeding biology of greater sandhill cranes (Grus canadensis tabida) on the Roseau River Wildlife Management Area in northwestern Minnesota wa.\u27I studied from April 1989 to October 1990. A minimum of 0.25 breeding pair per km2 of wetland and upland nested on the study area. Except for distances to nearest shrub from nest and random sites (P = 0.047), there were DO significant differences among mean habitat values or distributions of variables measured at nest and random sites (P \u3e 0.05). Mean clutch size was 1.88 ± 0.33 (SD) eggs for 17 clutches in 1989 and 1990. In 1990, estimated hatch dates for 13 clutches ranged from 21 May to 12 June (x = 30 May ± 6.6 days [SD]), apparent egg hatching success was 69.2% (n = 26), and apparent and Mayfield corrected nest success were 73.3% (n = IS) and 53.8% (n = 14), respectively

Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia

Mutations in CSF3R (colony-stimulating factor 3 receptor) are frequent oncogenic drivers in chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML). Here we describe a 75 year old man who was diagnosed with CSF3R-T618I-positive atypical CML. He presented with leukocytosis, anemia, and thrombocytopenia and developed massive splenomegaly and severe constitutional symptoms. Hydroxyurea was given over a 6 month period but failed to provide any measureable clinical benefit. Eventually, he was treated with ruxolitinib, an FDA-approved JAK1/2 inhibitor, which resulted in dramatic improvement of his blood counts. He also had significant reduction of spleen volume and constitutional symptoms. This case highlights the need for a clinical trial to interrogate JAK1/2 as a potential molecular target in CNL and aCML in patients with or without CSF3R mutation. A clinical trial evaluating the safety and efficacy of ruxolitinib for this patient population is registered at ClinicalTrials.gov (NCT02092324)